首页> International journal of cancer> Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.

Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.

导出原文传递

翻译打印收藏纠错

第一作者： Tilmann,Bochtler

第一单位： Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.;Department of Thoracic Oncology, Thoraxklinik Heidelberg, Heidelberg, Germany.;Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Germany.;Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.

作者： Tilmann,Bochtler ^[1] ; Anna,Reiling ^[2] ; Volker,Endris ^[3] ; Thomas,Hielscher ^[4] ; Anna-Lena,Volckmar ^[5] ; Olaf,Neumann ^[5] ; Martina,Kirchner ^[5] ; Jan,Budczies ^[5] ; Lukas C,Heukamp ^[6] ; Jonas,Leichsenring ^[5] ; Michael,Allgäuer ^[5] ; Daniel,Kazdal ^[5] ; Harald,Löffler ^[7] ; Wilko,Weichert ^[8] ; Peter,Schirmacher ^[5] ; Albrecht,Stenzinger ^[3] ; Alwin,Krämer ^[2]

作者单位： Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.;Department of Thoracic Oncology, Thoraxklinik Heidelberg, Heidelberg, Germany.;Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Germany.;Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany. ^[1] Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.;Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany. ^[2] Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.;German Cancer Consortium (DKTK), Germany. ^[3] Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany. ^[4] Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany. ^[5] Institute for Haematopathology Hamburg, Hamburg, Germany. ^[6] Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.;Marienhospital Stuttgart, Stuttgart, Germany. ^[7] Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.;German Cancer Consortium (DKTK), Germany.;Institute of Pathology, Technical University Munich, Munich, Germany. ^[8]

关键词 cancer of unknown primary mutational profiling prognosis targeted therapy